SCHEMBL2338313

SCHEMBL2338313

O=C(O)C(NCCNC(C(=O)O)c1ccc(O)cc1)c1ccc(O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 2/20 0.50
NAALAD2 Q9Y3Q0 1/20 0.50
SRC P12931 1/20 0.44
KMT2A Q03164 1/20 0.43
ATM Q13315 1/20 0.43
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
LMNA P02545 3/20 0.42
ALDH1A1 P00352 1/20 0.42
HSD17B10 Q99714 1/20 0.42
YARS1 P54577 1/20 0.41
SLC7A5 Q01650 1/20 0.40
ESR1 P03372 3/20 0.39
ESR2 Q92731 2/20 0.39
ADRB2 P07550 2/20 0.38
CYP2D6 P10635 2/20 0.38
SLC6A2 P23975 2/20 0.38
ADRA1A P35348 2/20 0.38
OPRM1 P35372 2/20 0.38
SLC6A3 Q01959 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15661797 1.00 FOLH1 (0.50) FOLH1NAALAD2SRCKMT2AATM
SCHEMBL15235867 0.91 FOLH1 (0.48) FOLH1NAALAD2SRCKMT2AATM
SCHEMBL10703073 0.89 FOLH1 (0.46) FOLH1NAALAD2SRCKMT2AATM
SCHEMBL31744459 0.86 KMT2A (0.42) FOLH1NAALAD2SRCKMT2AATM
SCHEMBL2728052 0.86 KMT2A (0.42) FOLH1NAALAD2SRCKMT2AATM
SCHEMBL11039517 0.85 FOLH1 (0.51) FOLH1NAALAD2SRCKMT2AATM
SCHEMBL14015971 0.83 MTOR (0.52) NAALAD2SRCKMT2ALMNAALDH1A1
SCHEMBL30368057 0.80 FOLH1 (0.44) FOLH1NAALAD2SRCKMT2AATM
SCHEMBL31402508 0.79 FOLH1 (0.49) FOLH1NAALAD2SRCKMT2AATM
SCHEMBL5427932 0.78 FOLH1 (0.55) FOLH1NAALAD2SRCKMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110206650-A1 Probiotic Formulations BRACCO IMAGING S.P.A. (IT) 2011-08-25 US claimed
EP-0145506-B1 ELIMINATION OF DEFECTS IN CYSTEINE-SENSITIZED EMULSIONS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-03-02 EP claimed
CN-122055172-A Chimeric radiopharmaceuticals targeting the proton-sensitive receptor GPR4 安菲利克斯股份公司 2026-05-15 CN disclosed
US-20260125407-A1 PROCESS FOR THE PREPARATION OF POLYAMINOCARBOXYLIC ACIDS AND CHELATE COMPOUNDS THEREOF VALAGRO S.P.A. (IT) 2026-05-07 US disclosed
US-12534488-B2 Process for the preparation of polyaminocarboxylic acids and chelate compounds thereof VALAGRO S.P.A. (IT) 2026-01-27 US disclosed
US-20250382259-A1 METHOD FOR PREPARING CHELATABLE EDDHA RAM TECHNOLOGY CO., LTD. (KR) 2025-12-18 US disclosed
WO-2025242909-A1 CD30-targeting antibody-radioligand conjugates and their therapeutic use PAUL SCHERRER INSTITUT (CH) 2025-11-27 WO disclosed
US-20250277247-A1 NUCLEIC ACID AMPLIFICATIONS IONIAN TECHNOLOGIES, LLC 2025-09-04 US disclosed
EP-4610269-A1 UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE 3B Pharmaceuticals GmbH (DE) 2025-09-03 EP disclosed
EP-4455159-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER 3B Pharmaceuticals GmbH (DE) 2024-10-30 EP disclosed
EP-4069673-B1 PROCESS FOR THE PREPARATION OF POLYAMINOCARBOXYLIC ACIDS AND CHELATE COMPOUNDS THEREOF VALAGRO SPA (IT) 2024-05-22 EP disclosed
US-20200131096-A1 Biofertilizer Composition and Method of Manufacture SUSTAINABLE COMMUNITY DEV LLC (US) 2020-04-30 US disclosed
US-9980479-B2 Method of reducing nematode damage SYNGENTA CROP PROTECTION, LLC (US) 2018-05-29 US disclosed
EP-1765079-B1 METHODS OF REDUCING NEMATODE DAMAGE SYNGENTA PARTICIPATIONS AG (CH) 2017-11-29 EP disclosed
US-20130231299-A1 METHODS FOR REDUCING NEMATODE DAMAGE SYNGENTA CROP PROTECTION LLC (US) 2013-09-05 US disclosed
US-20110206650-A1 Probiotic Formulations BRACCO IMAGING S.P.A. (IT) 2011-08-25 US disclosed
EP-0334630-B1 Iron chelate composition PHOSYN PLC (GB) 1993-11-18 EP disclosed
US-5152820-A Increasing iron concentration of soils PHOSYN PLC. (GB) 1992-10-06 US disclosed
EP-0334630-A1 Iron chelate composition PHOSYN PLC (GB) 1989-09-27 EP disclosed
EP-0145506-B1 ELIMINATION OF DEFECTS IN CYSTEINE-SENSITIZED EMULSIONS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125407-A1 PROCESS FOR THE PREPARATION OF POLYAMINOCARBOXYLIC ACIDS AND CHELATE COMPOUNDS THEREOF PAH, HAO2, AGXT FOLH1 719/4885NAALAD2 1748/4885SRC 2902/4885
US-12534488-B2 Process for the preparation of polyaminocarboxylic acids and chelate compounds thereof PAH, GRHPR, AGXT FOLH1 597/4885NAALAD2 1774/4885SRC 3177/4885
US-20250382259-A1 METHOD FOR PREPARING CHELATABLE EDDHA EDNRA, QDPR, DOHH FOLH1 17/4885NAALAD2 195/4885SRC 4829/4885
US-20130231299-A1 METHODS FOR REDUCING NEMATODE DAMAGE PCNA, CAT, GMNN FOLH1 1008/4885NAALAD2 213/4885SRC 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.